Sitagliptin Results in a Decrease of Truncated Apolipoprotein C1.
UNLABELLED
Apolipoprotein C1 (ApoC1) is a component of multiple lipoproteins where it performs a variety of roles in lipid metabolism and transport. ApoC1 exists as both full-length and truncated isoforms. Truncation of ApoC1 has been postulated to result from the action of dipeptidyl peptidase-4 (DPP-4), the target of a new class of diabetes drugs that includes sitagliptin phosphate. In this study, we sought to determine if oral administration of sitagliptin altered the proportion of ApoC1 isoforms circulating in humans. Results indicated a dramatic change in ApoC1 truncation, consistent with a high level of DPP-4 inhibition by sitagliptin.


FUNDING
University of Minnesota, Minneapolis, MN, USA.
['Skinner|Nicole E B|NE|', 'Wroblewski|Matthew S|MS|', 'Kirihara|Julie A|JA|', 'Nelsestuen|Gary L|GL|', 'Seaquist|Elizabeth R|ER|']
Sitagliptin Apolipoprotein C1 Mass spectrometry